Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed by HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $41.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 94.68% from the company’s current price.

Several other brokerages also recently weighed in on SNDX. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th. Finally, Scotiabank downgraded Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and decreased their target price for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.42.

Syndax Pharmaceuticals Trading Up 2.4 %

SNDX stock opened at $21.06 on Friday. The stock has a 50-day moving average price of $22.67 and a two-hundred day moving average price of $19.61. Syndax Pharmaceuticals has a 12-month low of $11.22 and a 12-month high of $25.34. The company has a market cap of $1.79 billion, a PE ratio of -7.11 and a beta of 1.03.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter in the previous year, the firm earned ($0.62) earnings per share. Equities analysts forecast that Syndax Pharmaceuticals will post -3.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $143,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 6.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,192 shares of the company’s stock valued at $613,000 after acquiring an additional 2,700 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $1,663,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 97.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock valued at $26,000 after acquiring an additional 880 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Syndax Pharmaceuticals by 5.1% in the third quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company’s stock valued at $227,000 after purchasing an additional 757 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).